Miami Patient Sees Remission in Leukemia Clinical Trial
A breakthrough study at the Sylvester Comprehensive Cancer Center offers hope for those with adverse-risk acute myeloid leukemia.
Updated on Oct. 24, 2026 in Cancer
In September 2024, a patient at the Sylvester Comprehensive Cancer Center achieved remission for acute myeloid leukemia after participating in a specialized clinical trial. The patient, Ryan Goepel, later successfully completed a bone marrow transplant to restore his immune system.
Why it matters
This clinical trial sought to determine if treatment regimens typically reserved for older patients are effective for younger individuals with similar high-risk genetic profiles. The research aims to improve outcomes for a diagnosis that historically carries a difficult five-year survival rate.
A study published in the journal Haematologica reports that 19 of 36 trial participants achieved complete remission. This outcome is measured against the approximately 30% five-year survival rate generally associated with acute myeloid leukemia.
The players
Sylvester Comprehensive Cancer Center
This Miami-based research institution serves as a leading facility for cancer diagnostics, clinical trials, and patient care.
Ryan Goepel
He is an acute myeloid leukemia patient whose recovery journey provided the basis for this medical case study.
The details
The treatment protocol involved a daily oral medication for 28 days combined with a daily infusion during the first week of the course. Following his remission, the patient underwent a bone marrow transplant from a match to support his recovery.
Timeline
Ryan Goepel was diagnosed with acute myeloid leukemia in September 2024.
The patient underwent a bone marrow transplant in November 2024.
Ryan Goepel married his girlfriend in November 2025.
The Big Picture
This story tracks the outcomes of the Haematologica acute myeloid leukemia clinical trial. It follows the precedent established by this research program, which evaluates the effectiveness of specific medication protocols for younger patients with complex genetic profiles.
Patients dealing with high-risk leukemia diagnoses may now have access to broader treatment options developed through recent clinical trials. These protocols represent a shift in how medical professionals approach immune system restoration through bone marrow transplantation.
The takeaway
Advancements in clinical trials continue to reshape the standard of care for high-risk blood cancers. Patients and their families are encouraged to consult with oncology specialists regarding eligibility for emerging medication protocols.
Further reading
For more information on current treatment research, visit our Cancer section.
